Company Overview of Kymab Limited
Kymab Limited, a biopharmaceutical company, engages in the discovery and development of human monoclonal antibody therapeutics. The company is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. The company focuses on using the Kymouse platform for the discovery, development, and commercialization of antibody based medicines. Kymab Limited was founded in 2009 and is based in Cambridge, United Kingdom.
Babraham Research Campus
Cambridge, CB22 3AT
Founded in 2009
Key Executives for Kymab Limited
Chairman and Chief Executive Officer
Senior Vice President of Technology Development
Consultant Finance Director
Compensation as of Fiscal Year 2014.
Kymab Limited Key Developments
Kymab Defends Patent Action in UK
Oct 9 13
Kymab announced that it has notified the English Court that it will defend the UK patent proceedings brought by Regeneron in respect of European patent EP1360287. Regeneron initiated these proceedings in September 2013. Kymab will defend the UK patent action on the grounds of non-infringement and invalidity of the patent. Earlier, in June 2013, Kymab opposed the equivalent Regeneron European patent in the European Patent Office. The opposition proceedings are pending.
Kymab Announces Kymouse Antibody Discovery Agreement with Novo Nordisk
Apr 22 13
Kymab announced an agreement in therapeutic antibody discovery. Novo Nordisk has been granted a non-exclusive licence to Kymab's proprietary Kymouse(TM) human antibody discovery platform to discover, develop and commercialise therapeutic monoclonal antibody drugs for human diseases. The licence provides Novo Nordisk with access to the Kymouse HK and Kymouse HL transgenic human antibody mouse strains, which can generate highly selective, potent, human antibody drug candidates. The Kymouse HL strain produces antibodies with human heavy and lambda light chains whereas Kymouse HK generates antibodies with human heavy and kappa light chains. By using these strains in combination, a diverse pool of human antibodies can be created with both classes of light chains fully represented.
Kymab Limited Presents at BioCapital Europe 2013, Apr-17-2013 11:40 AM
Apr 15 13
Kymab Limited Presents at BioCapital Europe 2013, Apr-17-2013 11:40 AM. Venue: Sofitel Amsterdam The Grand, Oudezijds Voorburgwal 197, 1012 EX Amsterdam, Netherlands.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 16, 2014
Most Searched Private Companies
Sponsored Financial Commentaries